- Medical imaging company EMVision (EMV) has recommenced enrolling patients in its clinical study at Brisbane’s Princess Alexandra Hospital
- The study is testing EMV’s portable brain imaging device in stroke patients
- The company had previously continued the study as planned in the early phases of the COVID-19 outbreak, but had to pause enrolments due to potential pandemic-related interruptions
- Now Queensland’s curve is flattening, the company is hoping to stay on track for the study’s original six-month timeframe
- EMVision is down 2.7 per cent to 89 cents per share
Medical imaging company EMVision (EMV) has recommenced enrolling patients in its clinical study at Brisbane’s Princess Alexandra Hospital.
The study is testing EMV’s portable brain imaging device in stroke patients.
The company had previously continued the study as planned in the early phases of the COVID-19 outbreak, but had to pause enrolments while it monitored potential pandemic-related interruptions.
Now Queensland’s curve is flattening and medical authorities no longer anticipate too much stress being placed on the health system, EMVision has been able to recommence enrolling patients, and may even be able to keep on track with the original six-month timeline for the program.
The company says it is continuing to monitor the COVID-19 situation, and any associated impacts on its trial work.
This includes access to clinical facilities and personnel which may be diverted due to pandemic-related public health needs.
EMVision says it will continue to provide updates to the market as the situation progresses and further clinical milestones are reached.
EMVision is down 2.7 per cent to 89 cents per share as at 12 pm AEST.